Melanie Carr
Impact in
-
- Pharmaceutical Economics and Policy
- Health Systems, Economic Evaluations, Quality of Life
Papers in
-
- SARS-CoV-2 and COVID-19 Research 1
- Co-authors
- Hans‐Georg Eichler (1 shared paper)Núria Porta (1 shared paper)Rosa Gonzalez‐Quevedo (2 shared papers)Jens Reinhardt (1 shared paper)Marco Cavaleri (1 shared paper)Patrick Celis (1 shared paper)Helen Ratcliffe (1 shared paper)Massimiano Bucchi (1 shared paper)
- Journals
- Health Policy and Technology (1 paper)EFSA Journal (1 paper)Nature Reviews Drug Discovery (1 paper)The Lancet Regional Health - Europe (1 paper)The Journal of Infectious Diseases (1 paper)
- Partner nations
- NetherlandsUnited KingdomGermany
In The Last Decade
Melanie Carr
10 papers receiving 108 citations
Peers
Comparison fields: 5 of 53
- Microbiology 8
- Economics and Econometrics 35
- Epidemiology 25
- Health 6
- Medical Laboratory Technology 1
Countries citing papers authored by Melanie Carr
This map shows the geographic impact of Melanie Carr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melanie Carr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melanie Carr more than expected).
Fields of papers citing papers by Melanie Carr
This network shows the impact of papers produced by Melanie Carr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melanie Carr. The network helps show where Melanie Carr may publish in the future.
Co-authors
The 25 scholars most cited alongside Melanie Carr, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2014 | 29 | |
| 2 | 2022 | 21 | |
| 3 | 2012 | 16 | |
| 4 | 2021 | 15 | |
| 5 | 2019 | 13 | |
| 6 | 2009 | 5 | |
| 7 | 2020 | 5 | |
| 8 | 2007 | 4 | |
| 9 | 2001 | 3 | |
| 10 | 2016 | 1 |
About Melanie Carr
Melanie Carr is a scholar working on Infectious Diseases, Public Health, Environmental and Occupational Health, Economics and Econometrics, Immunology and Radiological and Ultrasound Technology, having authored 10 papers that have together received 112 indexed citations. Recurring topics across this work include Biosimilars and Bioanalytical Methods (2 papers), Pharmaceutical Economics and Policy (2 papers), Pharmacovigilance and Adverse Drug Reactions (1 paper), Animal Disease Management and Epidemiology (1 paper), Ginkgo biloba and Cashew Applications (1 paper), SARS-CoV-2 and COVID-19 Research (1 paper), Pneumocystis jirovecii pneumonia detection and treatment (1 paper) and Genetically Modified Organisms Research (1 paper). The work is most often cited by research in Microbiology (8 citations), Economics and Econometrics (35 citations), Epidemiology (25 citations), Health (6 citations) and Medical Laboratory Technology (1 citation). Melanie Carr has collaborated with scholars based in Netherlands, United Kingdom and Germany. Frequent co-authors include Hans‐Georg Eichler, Núria Porta, Rosa Gonzalez‐Quevedo, Jens Reinhardt, Marco Cavaleri, Patrick Celis, Helen Ratcliffe, Massimiano Bucchi, Ellen Vos and Irina Tcherniaeva. Their work appears in journals such as Health Policy and Technology, EFSA Journal, Nature Reviews Drug Discovery, The Lancet Regional Health - Europe and The Journal of Infectious Diseases.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.